Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
JENLOGA vs ALYACEN 1/35
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
JENLOGA is a combination of sulfamethoxazole, a sulfonamide, and trimethoprim, a dihydrofolate reductase inhibitor. Sulfamethoxazole inhibits bacterial dihydrofolic acid synthesis by competing with para-aminobenzoic acid, while trimethoprim inhibits dihydrofolate reductase, blocking the conversion of dihydrofolic acid to tetrahydrofolic acid. This sequential blockade produces synergistic bactericidal activity.
Combination hormonal contraceptive: ethinyl estradiol suppresses gonadotropin release via negative feedback on hypothalamic-pituitary axis; norethindrone induces progestational effects including cervical mucus thickening and endometrial changes, inhibiting ovulation and sperm penetration.
Treatment of urinary tract infections due to susceptible strains of Escherichia coli, Klebsiella species, Enterobacter species, Morganella morganii, Proteus mirabilis, and Proteus vulgaris,Treatment of acute otitis media in children,Treatment of acute exacerbations of chronic bronchitis in adults,Treatment of enteritis caused by Shigella flexneri or Shigella sonnei,Prophylaxis and treatment of Pneumocystis jirovecii pneumonia,Treatment of traveler's diarrhea,Treatment of toxoplasmosis
Prevention of pregnancy
350 mg orally once daily with food.
One tablet (norethindrone 1 mg and ethinyl estradiol 35 mcg) orally once daily for 21 consecutive days, followed by 7 days of placebo or no tablets.
Terminal half-life 6-8 hours in healthy adults; prolonged to 12-15 hours in moderate renal impairment (Cr Cl 30-50 m L/min)
Norethindrone: 8-11 hours (terminal); ethinyl estradiol: 10-20 hours (terminal). The half-life supports once-daily dosing for oral contraceptive efficacy.
Sulfamethoxazole is primarily metabolized via N-acetylation (N-acetyltransferase 2) and glucuronidation. Trimethoprim is metabolized primarily by oxidative O-demethylation (CYP3A4, CYP1A2) and conjugation.
Ethinyl estradiol: primarily hepatic via CYP3A4; norethindrone: hepatic reduction and sulfate conjugation.
Renal (80% as unchanged drug), biliary/fecal (15% as metabolites and unchanged drug)
Renal excretion of metabolites (primarily ethinyl estradiol and norethindrone conjugates) accounts for approximately 50-60% of elimination; fecal excretion accounts for 30-40%. Unchanged drug excretion is minimal (<5%).
98% bound primarily to albumin
Norethindrone: 61% bound to albumin and SHBG; ethinyl estradiol: 97-98% bound to albumin.
0.15-0.3 L/kg, indicating limited extravascular distribution
Norethindrone: 3.8-4.5 L/kg; ethinyl estradiol: 2.0-4.0 L/kg. Large Vd indicates extensive tissue distribution.
Oral: 92% (high first-pass metabolism; extensive absorption)
Oral: Norethindrone ~64%, ethinyl estradiol ~38-48% (due to first-pass metabolism).
GFR ≥45 m L/min: no adjustment; GFR 30-44 m L/min: 350 mg every other day; GFR <30 m L/min or ESRD: not recommended.
No dose adjustment required for mild to moderate renal impairment. Contraindicated in severe renal impairment or acute renal failure due to potential fluid retention and electrolyte disturbances.
Child-Pugh A: no adjustment; Child-Pugh B: 200 mg once daily; Child-Pugh C: not recommended.
Contraindicated in patients with hepatic impairment, including Child-Pugh class B or C, due to impaired metabolism of estrogen and progestin. Not recommended in patients with active liver disease or history of liver tumors.
Not recommended for pediatric patients due to lack of safety and efficacy data.
Not indicated for use before menarche. For postmenarchal adolescents, same dosing as adults. Safety and efficacy established for contraception; weight-based dosing not applicable.
No specific dose adjustment recommended; monitor renal function closely in patients ≥65 years.
Not indicated for use after menopause due to lack of benefit and increased risks (e.g., cardiovascular, thromboembolic events). If used, monitor for fluid retention, hypertension, and glucose intolerance.
Fatal hypersensitivity reactions including Stevens-Johnson syndrome, toxic epidermal necrolysis, fulminant hepatic necrosis, agranulocytosis, aplastic anemia, and other blood dyscrasias have been reported with sulfonamides. JENLOGA is contraindicated in patients with a history of hypersensitivity to sulfonamides or trimethoprim.
Cigarette smoking increases risk of serious cardiovascular events from combined oral contraceptives. Risk increases with age and heavy smoking (≥15 cigarettes/day). Women over 35 who smoke should not use this product.
Fatal hypersensitivity reactions (Stevens-Johnson syndrome, toxic epidermal necrolysis); discontinue at first sign of rash,Hematologic toxicity including agranulocytosis, aplastic anemia; monitor CBC regularly,Hepatic necrosis; discontinue if signs of liver injury occur,Severe renal impairment (Cr Cl <15 m L/min); avoid use,Potential for hyperkalemia in patients with renal dysfunction or those on potassium-sparing diuretics,Risk of folate deficiency; monitor folate levels in chronic therapy,Photosensitivity; avoid prolonged sun exposure
Thrombotic disorders (e.g., DVT, PE, stroke, MI),Cerebrovascular disease,Hepatic neoplasia,Gallbladder disease,Hypertension,Carbohydrate and lipid effects,Ocular lesions,Hereditary angioedema,Chloasma,Menstrual irregularities,Pregnancy exclusion prior to initiation
Hypersensitivity to sulfonamides or trimethoprim,History of drug-induced immune thrombocytopenia with prior sulfonamides,Megaloblastic anemia due to folate deficiency,Severe renal impairment (Cr Cl <15 m L/min) unless for Pneumocystis jirovecii pneumonia treatment,Pregnancy at term and nursing mothers (due to potential for kernicterus in neonates),Concomitant use with dofetilide (increases risk of arrhythmias)
Venous or arterial thrombotic/thromboembolic disease (current or history),Cerebrovascular disease,Coronary artery disease,Known or suspected breast cancer,Endometrial or other estrogen-dependent neoplasia,Undiagnosed abnormal genital bleeding,Cholestatic jaundice of pregnancy or jaundice with prior pill use,Hepatic adenoma or carcinoma,Known or suspected pregnancy,Hypersensitivity to any component,Smoking in women over 35
Take with or without food. High-fat meals may delay absorption but no significant clinical impact. Avoid grapefruit and grapefruit juice as they may alter drug levels.
No significant food interactions. Grapefruit juice may increase estrogen levels, but clinically not a concern. Avoid excessive alcohol, which may impair liver function and increase estrogen exposure. Maintain a healthy diet, as weight gain is possible.
Pregnancy exposure registry data indicate increased risk of major congenital malformations, including neural tube defects, cardiovascular anomalies, and cleft palate, with first-trimester exposure. Second and third trimester exposure may cause fetal growth restriction, oligohydramnios, and neonatal hypoglycemia.
Pregnancy category X. Use of ALYACEN 1/35 (norethindrone/ethinyl estradiol) is contraindicated during pregnancy. First trimester: Increased risk of congenital anomalies, including cardiovascular defects and limb reduction defects. Second/third trimesters: Potential for urogenital abnormalities and feminization of male fetus. Exposure is associated with subsequent development of clear cell adenocarcinoma of vagina/cervix in female offspring (DES-related).
Not recommended during breastfeeding. M/P ratio not established; drug is excreted in human milk. Potential for serious adverse reactions in nursing infants.
Small amounts of contraceptive steroids and/or metabolites have been identified in breast milk. M/P ratio: Not specifically determined for this combination; ethinyl estradiol M/P ratio ~0.02-0.04. Use may reduce milk production and quality. Breastfeeding not recommended during use. Alternative contraception advised.
Dose adjustments required due to increased volume of distribution and enhanced clearance; monitor trough levels and adjust to maintain therapeutic range. Consider 30-50% dose increase in third trimester.
Contraindicated in pregnancy; no dose adjustments applicable. Discontinue medication immediately upon pregnancy detection.
Jenloga (cenobamate) is a tetrazole-derived antiepileptic drug. Titrate slowly to reduce risk of severe hypersensitivity reactions, including DRESS syndrome. Monitor for QT shortening on ECG. Dose adjustments needed in renal impairment. Consider lower starting dose in patients with hepatic impairment.
ALYACEN 1/35 is a combination oral contraceptive containing ethinyl estradiol 35 mcg and norgestimate 1 mg. It is indicated for the prevention of pregnancy and for the treatment of moderate acne vulgaris in females ≥15 years of age who desire an oral contraceptive. Monitor for thromboembolic events, especially in smokers over 35 or those with migraine with aura. Use with caution in patients with liver impairment or history of cholestatic jaundice. The pill-free interval should not exceed 7 days; missed pills increase ovulation risk. Consider non-hormonal backup if vomiting or diarrhea occurs within 4 hours of dosing.
Take exactly as prescribed; do not stop suddenly without medical advice.,Report any rash, fever, or swollen lymph nodes immediately.,Avoid alcohol and other CNS depressants.,Use effective contraception; drug may cause fetal harm.,Notify healthcare provider if you become pregnant or plan to.,May cause dizziness or somnolence; avoid driving until effects known.
Take one tablet daily at the same time each day; do not skip doses.,Use an additional non-hormonal contraceptive (e.g., condoms) if you miss a pill, have vomiting, or diarrhea.,Smoking while on this pill increases the risk of blood clots and stroke, especially if you are over 35.,Contact your healthcare provider immediately if you have chest pain, leg pain/swelling, sudden vision changes, or severe headache.,This medication does not protect against HIV or other sexually transmitted infections.,Store at room temperature, away from moisture and heat.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about JENLOGA vs ALYACEN 1/35, answered by our medical review team.
JENLOGA is a Oral Contraceptive that works by JENLOGA is a combination of sulfamethoxazole, a sulfonamide, and trimethoprim, a dihydrofolate reductase inhibitor. Sulfamethoxazole inhibits bacterial dihydrofolic acid synthesis by competing with para-aminobenzoic acid, while trimethoprim inhibits dihydrofolate reductase, blocking the conversion of dihydrofolic acid to tetrahydrofolic acid. This sequential blockade produces synergistic bactericidal activity.. ALYACEN 1/35 is a Oral Contraceptive that works by Combination hormonal contraceptive: ethinyl estradiol suppresses gonadotropin release via negative feedback on hypothalamic-pituitary axis; norethindrone induces progestational effects including cervical mucus thickening and endometrial changes, inhibiting ovulation and sperm penetration.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between JENLOGA and ALYACEN 1/35 depend on the specific clinical indication. These are both Oral Contraceptive agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of JENLOGA is: 350 mg orally once daily with food.. The standard adult dose of ALYACEN 1/35 is: One tablet (norethindrone 1 mg and ethinyl estradiol 35 mcg) orally once daily for 21 consecutive days, followed by 7 days of placebo or no tablets.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between JENLOGA and ALYACEN 1/35 in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. JENLOGA is classified as Category C. Pregnancy exposure registry data indicate increased risk of major congenital malformations, including neural tube defects, cardiovascular anomalies, and cleft palate, with first-tr. ALYACEN 1/35 is classified as Category C. Pregnancy category X. Use of ALYACEN 1/35 (norethindrone/ethinyl estradiol) is contraindicated during pregnancy. First trimester: Increased risk of congenital anomalies, including . Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.